Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Merck
Johnson and Johnson
Dow
Medtronic

Last Updated: December 12, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Vicriviroc

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Vicriviroc?

Vicriviroc is an investigational drug.

There have been 13 clinical trials for Vicriviroc. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2007.

The most common disease conditions in clinical trials are HIV Infections, Immunologic Deficiency Syndromes, and Acquired Immunodeficiency Syndrome. The leading clinical trial sponsors are Merck Sharp & Dohme Corp., National Institute of Allergy and Infectious Diseases (NIAID), and Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

Recent Clinical Trials for Vicriviroc
TitleSponsorPhase
Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)Merck Sharp & Dohme Corp.Phase 2
Pharmacokinetics of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048National Institute of Allergy and Infectious Diseases (NIAID)Phase 1
Safety and Immune Response to Vicriviroc in Combination Regimens in HIV-Infected ART Experienced Children and AdolescentsEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Phase 1/Phase 2

See all Vicriviroc clinical trials

Clinical Trial Summary for Vicriviroc

Top disease conditions for Vicriviroc
Top clinical trial sponsors for Vicriviroc

See all Vicriviroc clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Johnson and Johnson
Medtronic
Harvard Business School
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.